Newborn Baby Foot
Hospital
Mother and Son
Haematology
Grandma's Healing Touch
Lab Experiment
Little Boy Playing Doctor
Child In Hospital Bed
Examining an X-Ray
Man Running
Pipetting Samples and Test Tube

NEWS & PRESENTATIONS

ON AUGUST 6, 2020 THE COMPANY CHANGED ITS NAME TO IN8bio, Inc.
Recent News & Press Releases

September 17, 2020

IN8bio Names Kate Rochlin, PhD Assistant Vice President, Operations and Innovation

IN8bio, Inc. today announced that Kate Rochlin, PhD has been named Assistant Vice President for Operations and Innovation.  Dr. Rochlin is an accomplished scientist and entrepreneur with fourteen years of experience in research, development, and operations.

August 24, 2020

Incysus Therapeutics Announces Name Change to IN8bio, Inc. 

Incysus Therapeutics, Inc. today announced that it has changed its name to IN8bio, Inc. 

August 7, 2020

Incysus Therapeutics to Present at Solebury Trout Private Company Showcase

Incysus Therapeutics, Inc. announced that the Company will present an overview of the company and at the upcoming Summer Private Company Showcase 2020 hosted by Solebury Trout, Piper Sandler and White & Case.  The presentation will be Monday, August 10, 2020 at 3:00 p.m. Eastern Time. 

August 3, 2020

Incysus Therapeutics to Present at LifeSci Partners Summer Symposium

Incysus Therapeutics, Inc. announced that the Company will present at the 2020 LifeSci Partners Virtual Summer Symposium on Wednesday, August 5th.  William Ho, President, Chief Executive Officer, and co-founder of Incysus Therapeutics, will present a company update at 2:00 p.m. Eastern Time. 

June 2, 2020

First Patient Treated in Phase I Clinical Trial of Incysus Therapeutics Gamma Delta (γδ) T cell Immunotherapy For Patients with Newly Diagnosed Glioblastoma

Incysus Therapeutics, Inc. announced that the first patient in a Phase 1 clinical study titled, “Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma” has been treated at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham. Incysus’ Drug Resistant Immunotherapy (DRI) Is the First Genetically Engineered γδ T Cell Therapy to be Administered to a Patient.

May 28, 2020

Incysus Therapeutics Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Incysus Therapeutics, Inc. announced that data related to the Company’s ongoing Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma will be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 12, 2020

Incysus Therapeutics Treats First Patient in Phase I Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation

Incysus Therapeutics, Inc. announced that the first patient in a Phase 1 clinical study titled, “Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide” has been treated at The University of Kansas Cancer Center (KU Cancer Center). 

April 6, 2020

Incysus Therapeutics to Present at the 2020 Solebury Trout Virtual Investor Conference

Incysus Therapeutics, Inc. today announced that the Company the Company will present at the 2020 Solebury Trout Virtual Investor Conference on Tuesday, April 7th at 1:00pm Eastern Time. To access the presentation, please login here

March 31, 2020

Incysus Therapeutics to Present at the NYC Spring Oncology Investor Conference

Incysus Therapeutics, Inc. today announced that the Company the Company will present at the 2020 NYC Spring Oncology Investor Conference being held on March 31st and April 1st. William Ho, President and Chief Executive Officer of Incysus Therapeutics, will present a company update. 

February 26, 2020

Incysus Therapeutics Initiates Enrollment in Phase I Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly-Diagnosed Glioblastoma

Incysus Therapeutics, Inc. today announced that the Company has initiated a Phase 1 clinical study of a novel Drug Resistant Immunotherapy (DRI) technology for the treatment of patients with newly-diagnosed glioblastoma.  This trial is being conducted at the University of Alabama at Birmingham (UAB) and is now active and open for enrollment.

February 7, 2020

Incysus Therapeutics to Present at the 2020 BIO CEO & Investor Conference

Incysus Therapeutics, Inc. today announced that William Ho, President and Chief Executive Officer of Incysus will present at the 2020 BIO CEO & Investor Conference on Monday, February 10, 2020 at 1:15 p.m. Eastern Time.  The Conference will be held at the New York Marriott Marquis hotel on 1535 Broadway in New York City.

January 23, 2020

Incysus Therapeutics Announces Issuance of Foundational U.S. Patent Covering Use of Drug Resistant Immunotherapy (DRI) Technology for the Treatment of Cancer

Incysus Therapeutics, Inc. today announced that the USPTO has issued, U.S. Patent Number 10,543,233 titled “Drug Resistant Immunotherapy for Treatment of a Cancer.”  The patent broadly covers the use of genetic engineering to chemo-protect gamma-delta (γδ) T cells and allow simultaneous chemo-immunotherapy combinations for the treatment of cancer.

January 9, 2020

Incysus Therapeutics to Present at Biotech Showcase 2020

Incysus Therapeutics, Inc. today announced that William Ho, President and Chief Executive Officer of Incysus will present at the Biotech Showcase on Monday, January 13, 2020 at 3:15 p.m. Pacific Time in the Franciscan B Ballroom (Ballroom Level).  The conference will be held at the Hilton San Francisco Union Square, San Francisco, CA.